Abstract

After our previous meeting at Kettilo, two years ago, most of the participants indicated that they would like to meet every second year to update the recent knowledge and research frontiers in diagnosis and treatment of neuroendocrine gut and pancreatic tumors. We all felt that it was important to come together and have both formal presentations and informal discussions of different issues. This time I decided to concentrate upon some areas of particular interest where new information has emerged during the past few years. These include multiple endocrine neoplasia type 1, particular works on molecular genetics, so-called ECL-omas, neuroendocrine tumors of the gastric mucosa, the somatostatin analogue Sandostatin, which has turned out not only to be a therapeutic agent but also to have a potential role in diagnosis of neuroendocrine tumors, and finally alpha interferons and mechanisms of action in neuroendocrine tumors.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call